Cadence Pharmaceuticals, a biopharmaceutical company developing drug candidates for use in hospitals, priced 6 million shares at $9 last night, below its proposed $11-$13 range. The stock is expected to begin trading on the NASDAQ under the ticker CADX on Wednesday. Merrill Lynch managed the deal for the San Diego-based company.
